GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 1 [US9938335B2] | IBI-362 | IBI362 | LY-3305677 | LY3305677
Compound class:
Peptide
Comment: Mazdutide (IBI362 or LY3305677) is a dual glucagon-like peptide-1 and glucagon receptor agonist. It is an acylated long-acting synthetic single-chain peptide analogue of the mammalian intestinal hormone oxyntomodulin [4,6-7]. SMILES string was obtained from PubChem.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Ji J, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L et al.. (2025)
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. NEJM,. DOI: 10.1056/NEJMoa2411528 |
2. Ji L, Jiang H, An P, Deng H, Liu M, Li L, Feng L, Song B, Han-Zhang H, Ma Q et al.. (2021)
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine, 39: 101088. [PMID:34430840] |
3. Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, Li X, Pang S, Zhang L, Chen L et al.. (2023)
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun, 14 (1): 8289. [PMID:38092790] |
4. Mezo AR, Chen Y, Valenzuela FA, Qu H. (2018)
Glucagon and GLP-1 co-agonist compounds. Patent number: US9938335B2. Assignee: Eli Lilly and Co. Priority date: 16/06/2016. Publication date: 10/04/2018. |
5. Nalisa DL, Cuboia N, Dyab E, Jackson IL, Felix HJ, Shoki P, Mubiana M, Oyedeji-Amusa M, Azevedo L, Jiang H. (2024)
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne), 15: 1309118. [PMID:38440786] |
6. Pocai A. (2014)
Action and therapeutic potential of oxyntomodulin. Mol Metab, 3 (3): 241-51. [PMID:24749050] |
7. Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O'Dowd AK, Williams DM, Frederick CB, Beals CR, Stoch SA et al.. (2018)
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes. Diabetes, 67 (6): 1105-1112. [PMID:29545266] |